Table 3 Incidence of treatment-related adverse events
Any-grade in ≥ 5% of patients or any grade 3 TRAEs | N = 51 | |
|---|---|---|
Any grade n (%) | Grade 3 n (%) | |
Patients with ≥1 event | 39 (76.5) | 4 (7.8) |
Infusion-related reaction | 15 (29.4) | 0 |
Fatigue | 9 (17.6) | 0 |
Chills | 6 (11.8) | 0 |
Diarrhea | 5 (9.8) | 0 |
Dysgeusia | 4 (7.8) | 0 |
Pyrexia | 4 (7.8) | 0 |
Aspartate aminotransferase increased | 3 (5.9) | 0 |
Dry mouth | 3 (5.9) | 0 |
Nausea | 2 (3.9) | 1 (2.0) |
Gamma-glutamyltransferase increased | 1 (2.0) | 1 (2.0) |
Hypokalemia | 1 (2.0) | 1 (2.0) |
Lipase increased | 1 (2.0) | 1 (2.0) |
All immune-related TRAEs | ||
Patients with ≥1 event | 5 (9.8) | 0 |
Hypothyroidism | 2 (3.9) | 0 |
Pneumonitis | 2 (3.9) | 0 |
Hyperthyroidism | 1 (2.0) | 0 |
Sarcoidosis | 1 (2.0) | 0 |
Vitiligo | 1 (2.0) | 0 |